The present application provides a modified Brucella strain, its use as a medicament, and its use as a medicament for the treatment and/or prevention of brucellosis. The Brucella strain has been modified through an inactivation of the wzm gene. Further, the present application provides a pharmaceutical composition which comprises the modified Brucella strain, its use as a medicament, and its use as a medicament for the treatment and/or prevention of brucellosis. The present application also provides a kit which comprises the modified Brucella strain and a pharmaceutically acceptable carrier or diluent and its use for the treatment and/or prevention of brucellosis.

Methods and compositions for the treatment of Brucella induced diseases and disorders are disclosed herein. In preferred embodiments, the invention relates to vaccines. In additional embodiments, the invention relates to formulations capable of releasing said vaccines at a controlled rate of release in vivo. In further embodiments, the invention relates to modified strains of the bacteria Brucella melitensis and Brucella abortus. In still further embodiments, the invention relates to compositions that do not induce clinical symptoms or splenomegaly in a subject receiving said compositions.

The present disclosure relates to a fusion protein comprising BP26 and an antigenic polypeptide, and to a nanoarchitecture comprising same. A vaccine composition comprising the fusion protein, nanoarchitecture, or combination thereof of the present disclosure can be used to effectively prevent or treat pathogens or cancer, and thus can be used as a multi-purpose vaccine platform.

Methods and compositions for the treatment of Brucella induced diseases and disorders are disclosed herein. In preferred embodiments, the invention relates to a vaccine compositions and methods of vaccinating comprising: a Brucella canis comprising one or more attenuating gene knockouts; and a pharmaceutically acceptable vaccine carrier.

Bacterial pathogens have evolved means to succeed as pathogens by infecting without recognition by receptors triggering innate immunity, by suppressing induction of immunity and by inducing immune responses to antigens that confer no protectives immunity. Embodiments described herein circumvent these abilities in Salmonella so as to provide a vector system that induces maximal protective immune responses. Another major problem in using live attenuated bacterial vaccine vectors is the accumulation of attenuating mutations that confer a virulence and safety but which decrease the ability of the vaccine to invade cells in the MALT to colonize and persist in internal effector lymphoid tissues. The embodiments disclosed herein solve this problem in multiple ways by using regulated delayed in vivo shut off of virulence genes, regulated delayed synthesis of recombinant protective antigens and regulated delayed lysis in vivo to confer biological containment with no persistence of vaccine cells and no survival if excreted.

The proposed preparation and methods relate to medicinal microbiology and pharmacology, and relate to preparations exhibiting an immunostimulatory effect, which may be used for the prevention and treatment of oncological diseases. The essence of the preparation and methods consists in a primary component of the preparation including a polyvalent corpuscular antigen, prepared on the basis of Treponema pallidum culture strains. The proposed preparation exhibits an immunostimulatory effect, with a primary influence on components of T-cell immunity. The proposed preparation, in a preventative therapeutic application, is effective with regard to tumors of various histogenesis.

The present application provides a modified Brucella strain, its use as a medicament, and its use as a medicament for the treatment and/or prevention of brucellosis. The Brucella strain has been modified through an inactivation of the wzm gene. Further, the present application provides a pharmaceutical composition which comprises the modified Brucella strain, its use as a medicament, and its use as a medicament for the treatment and/or prevention of brucellosis. The present application also provides a kit which comprises the modified Brucella strain and a pharmaceutically acceptable carrier or diluent and its use for the treatment and/or prevention of brucellosis.

The present application provides a modified Brucella strain, its use as a medicament, and its use as a medicament for the treatment and/or prevention of brucellosis. The Brucella strain has been modified through an inactivation of the wzm gene. Further, the present application provides a pharmaceutical composition which comprises the modified Brucella strain, its use as a medicament, and its use as a medicament for the treatment and/or prevention of brucellosis. The present application also provides a kit which comprises the modified Brucella strain and a pharmaceutically acceptable carrier or diluent and its use for the treatment and/or prevention of brucellosis.

There is provided a molecule comprising a chain of seven or more contiguous units of 4,6-dideoxy-4-acylamido-α-pyranose each pair of units joined by a C.sub.1-C.sub.2 or a C.sub.1-C.sub.3 link, the chain having a terminal end and a reducing end, wherein the pyranose ring in the unit of the chain most distal from the reducing end is linked to a cap structure. The cap structure is not a 4,6-dideoxy-4-acylamido-α-pyranose. There are also provided vaccine compositions comprising the molecule and methods of vaccinating an animal against infection by a Brucella organism, including methods of distinguishing between a vaccinated and an infected animal. There are further provided novel methods of detecting the presence in a sample of an anti-Brucella antibody.

There is provided a molecule comprising a chain of seven or more contiguous units of 4,6-dideoxy-4-acylamido-α-pyranose, each pair of units joined by a C.sub.1-C.sub.2 or a C.sub.1-C.sub.3 link, the chain having a terminal end and a reducing end, wherein the pyranose ring in the unit of the chain most distal from the reducing end is linked to a cap structure. The cap structure is not a 4,6-dideoxy-4-acylamido-α-pyranose. There are also provided vaccine compositions comprising the molecule and methods of vaccinating an animal NI against infection by a Brucella organism, including methods of distinguishing between a vaccinated and an infected animal. There are further provided novel methods of detecting the presence in a sample of an anti-Brucella antibody.